JP Morgan Chase’s Celgene Corporation Contingent Value Rights CELGZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q3
Sell
-92
Closed 5103
2016
Q2
$0 Hold
92
﹤0.01% 5233
2016
Q1
$0 Hold
92
﹤0.01% 5260
2015
Q4
$0 Buy
+92
New +$122 ﹤0.01% 4979
2013
Q4
Sell
-17,004
Closed -$137K 4496
2013
Q3
$137K Sell
17,004
-4,750
-22% -$36.6K ﹤0.01% 4125
2013
Q2
$159K Buy
+21,754
New +$158K ﹤0.01% 4053

Other funds holding CELGZ

JP Morgan Chase's CELGZ Position: Q3 2016 in Review

JP Morgan Chase sold out of Celgene Corporation Contingent Value Rights (CELGZ) in Q3 2016, closing a stake of 92 shares.

JP Morgan Chase first reported a position in CELGZ in Q2 2013 and held it in 5 quarters. The position peaked at $159K in Q2 2013. 26 funds tracked by Wall St. Rank hold CELGZ as of Q3 2016.

  • JP Morgan Chase reported no remaining Celgene Corporation Contingent Value Rights position as of Q3 2016 after selling out during the quarter.
  • JP Morgan Chase sold 92 Celgene Corporation Contingent Value Rights shares in Q3 2016.
  • JP Morgan Chase first reported a position in Celgene Corporation Contingent Value Rights in Q2 2013 and held it in 5 quarters.
  • JP Morgan Chase's Celgene Corporation Contingent Value Rights position peaked at $159K in Q2 2013.
  • 26 funds tracked by Wall St. Rank held Celgene Corporation Contingent Value Rights as of Q3 2016.

Based on JP Morgan Chase's 13F filing for Q3 2016, filed 4 Nov 2016.